Demographic and clinicopathologic features of 87 patients with NK/T-cell lymphoma treated with the SMILE regimen
| Clinicopathologic parameter . | Newly diagnosed . | Relapse/refractory . | Overall . |
|---|---|---|---|
| No. | 43 | 44 | 87 |
| Sex | |||
| Male | 25 | 34 | 59 |
| Female | 18 | 10 | 28 |
| Median age (range), y | 53 (26-83) | 49 (23-73) | 51 (23-83) |
| Median time to relapse (range), mo* | NA | 6 (1-168) | NA |
| Primary site (%)† | |||
| Nasal | 29 | 31 | 60 (69) |
| Nonnasal | 11 | 10 | 21 (24) |
| Disseminated | 3 | 3 | 6 (7) |
| Other involved sites (%)‡ | |||
| Multiple sites | 20 | 12 | 32 (37) |
| Lymph nodes | 2 | 7 | 9 (10) |
| Skin | 0 | 4 | 4 (5) |
| liver | 0 | 1 | 1 (1) |
| Spleen | 0 | 1 | 1 (1) |
| Testis | 0 | 1 | 1 (1) |
| Gastrointestinal tract | 2 | 2 | 4 (5) |
| Raised lactate dehydrogenase§ | 26 | 22 | 48 (55) |
| Hypoalbuminemia‖ | 25 | 26 | 51 (59) |
| Histologic involvement | |||
| Bone marrow | 14 | 7 | 21 (24) |
| Peripheral blood | 1 | 2 | 3 (3) |
| ECOG performance status (%) | |||
| 0 | 26 | 30 | 56 (64) |
| 1 | 11 | 10 | 21 (24) |
| 2 | 6 | 4 | 10 (11) |
| Stage (%) | |||
| I | 12 | 13 | 25 (29) |
| II | 5 | 8 | 13 (15) |
| III | 0 | 2 | 2 (2) |
| IV | 26 | 21 | 47 (54) |
| IPI (%) | |||
| Low (0 or 1) | 16 | 18 | 34 (39) |
| Intermediate low (2) | 7 | 9 | 16 (18) |
| Intermediate high (3) | 11 | 14 | 25 (29) |
| High (4 or 5) | 9 | 3 | 12 (14) |
| Korean prognostic scoring (%) | |||
| 0 | 10 | 10 | 20 (23) |
| 1 | 7 | 10 | 17 (20) |
| 2 | 4 | 9 | 13 (15) |
| 3 | 8 | 9 | 17 (20) |
| 4 | 14 | 4 | 18 (21) |
| Clinicopathologic parameter . | Newly diagnosed . | Relapse/refractory . | Overall . |
|---|---|---|---|
| No. | 43 | 44 | 87 |
| Sex | |||
| Male | 25 | 34 | 59 |
| Female | 18 | 10 | 28 |
| Median age (range), y | 53 (26-83) | 49 (23-73) | 51 (23-83) |
| Median time to relapse (range), mo* | NA | 6 (1-168) | NA |
| Primary site (%)† | |||
| Nasal | 29 | 31 | 60 (69) |
| Nonnasal | 11 | 10 | 21 (24) |
| Disseminated | 3 | 3 | 6 (7) |
| Other involved sites (%)‡ | |||
| Multiple sites | 20 | 12 | 32 (37) |
| Lymph nodes | 2 | 7 | 9 (10) |
| Skin | 0 | 4 | 4 (5) |
| liver | 0 | 1 | 1 (1) |
| Spleen | 0 | 1 | 1 (1) |
| Testis | 0 | 1 | 1 (1) |
| Gastrointestinal tract | 2 | 2 | 4 (5) |
| Raised lactate dehydrogenase§ | 26 | 22 | 48 (55) |
| Hypoalbuminemia‖ | 25 | 26 | 51 (59) |
| Histologic involvement | |||
| Bone marrow | 14 | 7 | 21 (24) |
| Peripheral blood | 1 | 2 | 3 (3) |
| ECOG performance status (%) | |||
| 0 | 26 | 30 | 56 (64) |
| 1 | 11 | 10 | 21 (24) |
| 2 | 6 | 4 | 10 (11) |
| Stage (%) | |||
| I | 12 | 13 | 25 (29) |
| II | 5 | 8 | 13 (15) |
| III | 0 | 2 | 2 (2) |
| IV | 26 | 21 | 47 (54) |
| IPI (%) | |||
| Low (0 or 1) | 16 | 18 | 34 (39) |
| Intermediate low (2) | 7 | 9 | 16 (18) |
| Intermediate high (3) | 11 | 14 | 25 (29) |
| High (4 or 5) | 9 | 3 | 12 (14) |
| Korean prognostic scoring (%) | |||
| 0 | 10 | 10 | 20 (23) |
| 1 | 7 | 10 | 17 (20) |
| 2 | 4 | 9 | 13 (15) |
| 3 | 8 | 9 | 17 (20) |
| 4 | 14 | 4 | 18 (21) |
NA indicates not applicable; and ECOG, Eastern Cooperative Oncology Group.
Either time from diagnosis to refractory disease, or time from last remission to relapse.
Symptomatic site that was initially biopsied.
Involved sites that were asymptomatic or shown up on imaging studies.
Higher than the upper limit of normal taken in the respective institutes.
Lower than the lower limit of normal in the respective institutes.